Glioma Clinical Trials in Philadelphia, Pennsylvania

6 studies are recruiting for glioma in Philadelphia, Pennsylvania right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

   The purpose of this study is to see if combining silevertinib with temozolomide after surgery and radiotherapy helps treat newly diagnosed glioblastoma (GBM) better than using temozolomide alone in the maintenance setting. Specifically, this study is being done to find answers to the following ques…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Thomas Jefferson University, Sidney Kimmel Comprehensive Cancer Center, Philadelphia, Pennsylvania

   Locations

   30 in total

   Run by

   Black Diamond Therapeutics, Inc.

   See if you can join NCT07326566 on ClinicalTrials.gov

2. SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

   This is a 3-part study. The purpose of Part 1 of the study is to evaluate the efficacy, safety, and pharmacokinetic (PK) characteristics of safusidenib in participants with recurrent/progressive IDH1-mutant World Health Organization (WHO) Grade 2 or Grade 3 glioma. The purpose of Part 2 will be to …

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Thomas Jefferson University Hospital, Philadelphia, Pennsylvania

   Locations

   61 in total

   Run by

   Nuvation Bio Inc.

   See if you can join NCT05303519 on ClinicalTrials.gov

3. Evaluation of 18F-Fluciclovine Positron Emission Tomography - Magnetic Resonance Imaging (PET-MRI) in LGG

   The purpose of this study is to see if 18F-Fluciclovine (Axumin®) is useful and safe in the management of children with Low Grade Gliomas (LGG). Imaging with 18F-Fluciclovine PET-MRI will be performed prior to initiation of therapy for LGG, and then 3 months, and 1 year after starting therapy. Chan…

   Stage

   EARLY_Phase 1

   Ages

   1 to 21

   Site

   The Children s Hospital of Philadelphia, Philadelphia, Pennsylvania

   Run by

   Children's Hospital of Philadelphia

   See if you can join NCT05555550 on ClinicalTrials.gov

4. ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)

   This is a randomized, double-blind, placebo-controlled, parallel-group, international, Phase 3 study in patients with newly diagnosed H3 K27M-mutant diffuse glioma to assess whether treatment with dordaviprone (ONC201) following frontline radiotherapy will extend overall survival and progression-fr…

   Stage

   Phase 3

   Ages

   Any age

   Site

   University of Pennsylvania, Philadelphia, Pennsylvania

   Locations

   162 in total

   Run by

   Jazz Pharmaceuticals

   See if you can join NCT05580562 on ClinicalTrials.gov

5. All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma

   This is a Phase II study of the combination of All-Trans Retinonic Acid (ATRA) and PD-1 inhibition (Retifanlimab) in patient with recurrent IDH-mutant glioma. The Sponsor-Investigator hypothesizes that the proposed regimen will be safe and stimulate a robust anti-tumor immune response.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Pennsylvania, Philadelphia, Pennsylvania

   Run by

   Stephen Bagley, MD, MSCE

   See if you can join NCT05345002 on ClinicalTrials.gov

6. 18F-Fluciclovine PET-MRI in High-grade Glioma

   The purpose of this study is to see if 18F-fluciclovine (Axumin®) PET imaging is useful and safe in the management of children with High Grade Gliomas. Investigators seek to determine if this imaging will help doctors tell the difference between tumor growth (progression) and other tumor changes th…

   Stage

   EARLY_Phase 1

   Ages

   1 to 21

   Site

   Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

   Run by

   Children's Hospital of Philadelphia

   See if you can join NCT05553041 on ClinicalTrials.gov